Menu Back toSession-0501-Drug-Safety-in-Clinical-Development-Benefit-Risk-Based-Decision
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
The 7th DIA China Annual Meeting
Session 0501 Drug Safety in Clinical Development – Benefit / Risk Based Decision
- Director, Associate Safety Risk Lead (Associate SR
- Pfizer (China) Research and Development Co.,Ltd, China
- Site Head, Drug Safety, Asia Pacific
- Genentech, a Member of Roche Group, China
Safety Surveillance& Risk Management in Drug Development
Ayman Ayoub, MD, MSc
- Executive Director
- Pfizer LTD Central Research, United Kingdom
The Value of Drug Safety in Drug Development
- Genentech Inc., United States